BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | Nov 17, 2017
Clinical News

Paion's remimazolam meets in Phase III trial for procedural sedation

Paion AG (Xetra:PA8) reported data from a Phase III trial in 431 patients undergoing bronchoscopy showing that procedural sedation with remimazolam (CNS 7056, ONO-2745) met the composite primary endpoint vs. both placebo and midazolam of...
BC Week In Review | Jul 18, 2016
Company News

Paion, Cosmo deal

Paion granted Cosmo’s Cosmo Technologies Ltd. subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting GABA A receptor modulator. Paion will receive EUR10 million ($11 million) up front and is eligible for up...
BC Week In Review | Dec 14, 2015
Clinical News

Remimazolam: Phase III started

Paion began a double-blind, U.S. Phase III trial to compare IV remimazolam vs. placebo and open-label midazolam in about 75 high-risk patients undergoing a colonoscopy. Patients will receive 2.5-5 mg initial doses of remimazolam followed...
BC Extra | Jul 25, 2015
Company News

Management tracks

Gene therapy play Avalanche Biotechnologies Inc. (NASDAQ:AAVL) said Thomas Chalberg resigned as president, CEO and a director. EVP of Business Operations Hans Hull will be interim CEO. Oncology play Mologen AG (Xetra:MGN) named Mariola Soehngen...
BC Week In Review | Jun 22, 2015
Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in 460 patients undergoing bronchoscopies. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance. Paion...
BC Week In Review | Apr 13, 2015
Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in about 460 patients undergoing colonoscopy. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance....
BC Extra | Dec 18, 2014
Clinical News

Well-traveled desmoteplase finally hits the wall

H. Lundbeck A/S (CSE:LUN) said it will cease development of desmoteplase (DPSA) to treat acute ischemic stroke. The compound, which has been in development for more than a decade and failed a Phase III study...
Items per page:
1 - 10 of 181
BC Extra | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

Kite’s KTE-X19 under review in Europe   EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BC Week In Review | Nov 17, 2017
Clinical News

Paion's remimazolam meets in Phase III trial for procedural sedation

Paion AG (Xetra:PA8) reported data from a Phase III trial in 431 patients undergoing bronchoscopy showing that procedural sedation with remimazolam (CNS 7056, ONO-2745) met the composite primary endpoint vs. both placebo and midazolam of...
BC Week In Review | Jul 18, 2016
Company News

Paion, Cosmo deal

Paion granted Cosmo’s Cosmo Technologies Ltd. subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting GABA A receptor modulator. Paion will receive EUR10 million ($11 million) up front and is eligible for up...
BC Week In Review | Dec 14, 2015
Clinical News

Remimazolam: Phase III started

Paion began a double-blind, U.S. Phase III trial to compare IV remimazolam vs. placebo and open-label midazolam in about 75 high-risk patients undergoing a colonoscopy. Patients will receive 2.5-5 mg initial doses of remimazolam followed...
BC Extra | Jul 25, 2015
Company News

Management tracks

Gene therapy play Avalanche Biotechnologies Inc. (NASDAQ:AAVL) said Thomas Chalberg resigned as president, CEO and a director. EVP of Business Operations Hans Hull will be interim CEO. Oncology play Mologen AG (Xetra:MGN) named Mariola Soehngen...
BC Week In Review | Jun 22, 2015
Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in 460 patients undergoing bronchoscopies. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance. Paion...
BC Week In Review | Apr 13, 2015
Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in about 460 patients undergoing colonoscopy. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance....
BC Extra | Dec 18, 2014
Clinical News

Well-traveled desmoteplase finally hits the wall

H. Lundbeck A/S (CSE:LUN) said it will cease development of desmoteplase (DPSA) to treat acute ischemic stroke. The compound, which has been in development for more than a decade and failed a Phase III study...
Items per page:
1 - 10 of 181